Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews how SALT scores are used in clinical trials for alopecia areata and provides patient images to help clinicians understand and apply these scores in practice; it reports no new clinical results.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.

This study found that 79% of adolescents with moderate-to-severe alopecia areata treated with baricitinib experienced significant scalp hair regrowth, although further research is needed to confirm these results.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

In this study, researchers developed an open-source browser-based tool to enhance the reproducibility and accuracy of SALT score calculations from scalp photos, aimed particularly at assessing partial regrowth in alopecia areata patients on JAK inhibitor therapy.

In this retrospective case series, baricitinib showed effectiveness in treating alopecia areata, with some potential benefits for psoriasis, but it may not be suitable for managing psoriatic arthritis in patients with these coexisting conditions.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

In this retrospective case series, baricitinib showed effectiveness in treating severe alopecia areata but had mixed results for psoriasis and was not optimal for psoriatic arthritis in patients with coexisting conditions, suggesting further studies are needed.

This study found that only a small percentage of alopecia areata patients treated with baricitinib in real-world settings would have met the eligibility criteria used in clinical trials.

In this study, patients with alopecia areata indicated a preference for shared decision-making (SDM) with their dermatologists, and those who engaged in SDM reported less decisional regret about their treatment choices.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

This paper reviews existing and emerging therapies for alopecia areata, describing the impact of targeted treatments in this field, and introduces a global network of disease registers to study the long-term safety and effectiveness of these new options.

This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

This research presents the Dodatek A model, elaborating on androgen function through new mathematical indices and methodological improvements, shifting focus from serum hormone concentrations to system interactions to better describe androgen activity comprehensively.

This study surveyed Irish dermatologists and found that while JAK inhibitors show promising efficacy for alopecia areata, there is significant variation in practice due to the lack of specific guidelines and long-term safety data for these treatments.